...
首页> 外文期刊>Transplantation Proceedings >Immunomonitoring of renal transplant recipients in the early posttransplant period by sequential analysis of chemokine and chemokine receptor gene expression in peripheral blood mononuclear cells.
【24h】

Immunomonitoring of renal transplant recipients in the early posttransplant period by sequential analysis of chemokine and chemokine receptor gene expression in peripheral blood mononuclear cells.

机译:通过顺序分析外周血单个核细胞中的趋化因子和趋化因子受体基因表达,在移植后早期对肾移植受体进行免疫监测。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: We sought to determine whether sequential changes in chemokine ligand/receptor gene expression in the early posttransplant period of human renal allografts can be detected in peripheral blood mononuclear cells (PBMCs) and whether any such changes are predictive of clinical events. METHODS: Blood samples from 106 renal transplant recipients and 29 donor nephrectomy patients were taken preoperatively and daily for 14 days. Within the study period 22 patients had biopsy-proven acute rejection. From each blood sample PBMCs were separated and gene expression levels for chemokines CCL3, CCL4, CCL5, CXCL10, and their receptors CCR1, CCR5, and CXCR3, were determined using real-time quantitative PCR. RESULTS: Different gene expression patterns were seen between the rejector and nonrejector groups with decreases in CCL4 and CCR5 expression on days 6 to 8 and increases in CCR1 expression on days 9 and 10 posttransplant. With CXCL10, decreases in expression were seen in the nonrejector group but increases were seen in the rejector group posttransplant. With data aligned to time of rejection diagnosis, statistically significant increases, that preceded the clinical detection of acute rejection were seen in CCR1 and CXCL10 expression. Both their expression levels returned to pretransplant baseline values after successful antirejection therapy. CONCLUSION: We have demonstrated that changes in chemokine receptor/ligand gene expression by sequential monitoring in PBMCs can be detected in the early posttransplant period. In particular, CCR1 and CXCL10, which showed increased expression prior to rejection and returned to baseline levels with antirejection therapy, may have potential use in immunomonitoring and as predictive factors of rejection prior to its clinical manifestation.
机译:引言:我们试图确定是否可以在外周血单核细胞(PBMC)中检测到人类肾脏同种异体移植后趋化因子配体/受体基因表达的顺序变化,以及是否有任何此类变化可预测临床事件。方法:术前每天抽取106名肾移植受者和29名供体肾切除术患者的血样,每天抽血14天。在研究期内,有22名患者经活检证实为急性排斥反应。从每个血液样本中分离PBMC,并使用实时定量PCR测定趋化因子CCL3,CCL4,CCL5,CXCL10及其受体CCR1,CCR5和CXCR3的基因表达水平。结果:排斥和非排斥组之间观察到不同的基因表达模式,在移植后第6至8天CCL4和CCR5表达降低,在移植后9和10天CCR1表达升高。使用CXCL10,在移植后非排斥反应组中表达降低,而在排斥反应组中表达升高。根据与排斥反应诊断时间一致的数据,在CCR1和CXCL10表达中发现了在临床上发现急性排斥反应之前的统计学显着增加。成功的抗排斥疗法后,它们的两种表达水平均恢复到移植前的基线值。结论:我们已经证明通过顺序监测PBMC中趋化因子受体/配体基因表达的变化可以在移植后的早期检测到。尤其是,CCR1和CXCL10在排斥之前表现出增加的表达,并通过抗排斥疗法恢复到基线水平,可能在免疫监测中具有潜在用途,并在其临床表现之前作为排斥的预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号